ELDN vs. SPRY, AVDL, BCYC, ZYME, SEPN, NUVB, PSTX, COLL, GYRE, and COGT
Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include ARS Pharmaceuticals (SPRY), Avadel Pharmaceuticals (AVDL), Bicycle Therapeutics (BCYC), Zymeworks (ZYME), Septerna (SEPN), Nuvation Bio (NUVB), Poseida Therapeutics (PSTX), Collegium Pharmaceutical (COLL), Gyre Therapeutics (GYRE), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.
Eledon Pharmaceuticals vs.
Eledon Pharmaceuticals (NASDAQ:ELDN) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.
56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 11.7% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 40.1% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Eledon Pharmaceuticals has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500.
ARS Pharmaceuticals' return on equity of -22.56% beat Eledon Pharmaceuticals' return on equity.
ARS Pharmaceuticals has higher revenue and earnings than Eledon Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Eledon Pharmaceuticals currently has a consensus target price of $16.00, indicating a potential upside of 331.27%. ARS Pharmaceuticals has a consensus target price of $26.00, indicating a potential upside of 128.87%. Given Eledon Pharmaceuticals' higher probable upside, equities research analysts plainly believe Eledon Pharmaceuticals is more favorable than ARS Pharmaceuticals.
Eledon Pharmaceuticals received 6 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 84.00% of users gave ARS Pharmaceuticals an outperform vote while only 72.97% of users gave Eledon Pharmaceuticals an outperform vote.
In the previous week, ARS Pharmaceuticals had 10 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 14 mentions for ARS Pharmaceuticals and 4 mentions for Eledon Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.83 beat Eledon Pharmaceuticals' score of 0.46 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.
Summary
ARS Pharmaceuticals beats Eledon Pharmaceuticals on 14 of the 17 factors compared between the two stocks.
Get Eledon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eledon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ELDN) was last updated on 1/15/2025 by MarketBeat.com Staff
Free ELDN Stock Alerts